Patents Examined by Thea D'Ambrosio
  • Patent number: 12364735
    Abstract: The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: July 22, 2025
    Assignee: ABIONYX PAHRMA SA
    Inventors: Jean-Louis Dasseux, Rose Ackermann, Daniela Carmen Oniciu
  • Patent number: 12350303
    Abstract: The presently disclosed subject matter relates to tumor infiltrated T cells induced by oncolytic virus (“OV-induced T cells”), methods of making and using said OV-induced T cells for an adoptive T-cell therapy. The presently disclosed subject matter further relates to oncolytic viruses and armed oncolytic viruses, methods of making and using said oncolytic viruses, as well as pharmaceutical compositions and kits comprising said oncolytic viruses.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: July 8, 2025
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Zong Sheng Guo, David Bartlett, Zuqiang Liu, Mathilde Feist
  • Patent number: 12331103
    Abstract: Provided herein are chimeric antigen receptors (CARs) for binding with a target antigen, comprising at least one antigen specific targeting region comprising a fibronectin type 3 (FN3) domain polypeptide. Provided herein are multispecific chimeric antigen receptors for binding with two or more target antigens, comprising at least two antigen specific targeting regions comprising a fibronectin type 3 domain polypeptide. Also provided herein are compositions and methods of treatment relating to the use of subject CARs of the invention.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: June 17, 2025
    Assignee: PROTELICA, INC.
    Inventors: Roberto Crea, Jun Yoon, Craig A. Hokanson, Emanuela Zacco
  • Patent number: 12285460
    Abstract: The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: April 29, 2025
    Assignee: RHYTHM PHARMACEUTICALS, INC.
    Inventors: Shubh Sharma, Leonardus H. T. Van Der Ploeg, Bart T. Henderson
  • Patent number: 12286455
    Abstract: The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: April 29, 2025
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Loic Le Hir de Fallois, Greg Pacofsky, Alan Long, Charles Meng, Hyoung Ik Lee, Cyprian O. Ogbu
  • Patent number: 12275977
    Abstract: A method for biologically producing acetin such as monoacetin, diacetin, or triacetin according to an embodiment of the present disclosure includes reacting acetyl-CoA with glycerol in the presence of a first O-acetyl transferase to obtain the acetin. With the method, acetin which is sustainable and safe, and has more excellent quality while not causing environmental pollution may be obtained.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: April 15, 2025
    Assignees: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY, KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Seon Won Kim, Seong Hee Jeong, Kyung Jin Kim, Zada Bakht
  • Patent number: 12268746
    Abstract: Polypeptides which can provide a senotherapeutic effect are provided herein. The polypeptides can be formulated for topical application and can be applied topically to a subject to provide a senotherapeutic effect in the subject or in the cells of the subject.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: April 8, 2025
    Assignees: OneSkin, Inc., Universidade Catolica de Brasilia, Uniao Brasileira de Educacao Catolica, Brasilia
    Inventors: Alessandra Zonari, Carolina Reis de Oliveira, Edgar Andres Ochoa, Juliana Lott de Carvalho, Lear Brace, Mariana Boroni, Mylieneth Guiang, Octávio Franco, William Farias Porto, Thuany de Alencar e Silva
  • Patent number: 12268747
    Abstract: Polypeptides which can provide a senotherapeutic effect are provided herein. The polypeptides can be formulated for topical application and can be applied topically to a subject to provide a senotherapeutic effect in the subject or in the cells of the subject.
    Type: Grant
    Filed: May 24, 2024
    Date of Patent: April 8, 2025
    Assignees: OneSkin, Inc., Universidade Catolica de Brasilia, Uniao Brasileira de Educacao Catolica, Brasilia
    Inventors: Alessandra Zonari, Carolina Reis de Oliveira, Edgar Andres Ochoa, Juliana Lott de Carvalho, Lear Brace, Mariana Boroni, Mylieneth Guiang, Octávio Franco, William Farias Porto, Thuany de Alencar e Silva
  • Patent number: 12264347
    Abstract: A composition comprising a recombinant enzyme that comprises a fusion of: a cyclobutane pyrimidine dimer photolyase corresponding to an amino acid encoding sequence having at least 85% sequence identity to SEQ ID NO 1, a pyrimidine(6-4)pyrimidone photolyase corresponding to an amino acid encoding sequence having at least 85% sequence identity to SEQ ID NO 2, and a skin penetrating peptide.
    Type: Grant
    Filed: December 14, 2019
    Date of Patent: April 1, 2025
    Inventor: Jeroen Hofenk
  • Patent number: 12221495
    Abstract: The present invention is aimed for providing a novel peptide with a high drug efficacy and strong effect, a medicament or external preparation comprising it, specifically a prophylactic or therapeutic for dermatitis, rhinitis or alopecia, or a hair growth stimulant, a hair growing agent, an antipruritic or a skin-care product. The present invention achieved said aim by providing a cyclic peptide having an amino acid sequence expressed by the Formula I or a derivative thereof or a pharmaceutically acceptable salt thereof, wherein the amino acid sequence does not have a peptide bond that is not between the amino acids constituting the amino acid sequence.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: February 11, 2025
    Assignee: Igisu Co., Ltd.
    Inventors: Kyoko Endo, Yori Endo
  • Patent number: 12221620
    Abstract: The present invention refers to a bioactive coating material for coating plastic materials for cell cultures, comprising a polymer conjugate of each a polymer anchor molecule having surface active anchoring groups and one or more biologically active molecules. The anchor molecule is an amphiphilic molecule with a hydrophobic moiety of styrene-, methacrylic acid-, isobutene-, acrylic acid-, acrylic acid ester-, or methacrylic acid ester units and a hydrophilic moiety of units including carboxyl-, amino-, epoxide-, thiol-, alkine- or azide groups. By selecting cell instructive coating materials cell destiny choices are individually and effectively controllable, in particular, the cell adhesion of almost any cell culture one-way articles by the user. With this concept, new options open up for high-throughput-diagnostics, stem cell-biotechnology and regenerative therapies.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: February 11, 2025
    Assignee: Zeta SCIENCE GmbH
    Inventor: Uwe Freudenberg
  • Patent number: 12221494
    Abstract: Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment of a retinal degenerative disease or tissue injury. Also disclosed herein are methods of treating a retinal degenerative disease or tissue injury, by administering to a subject in need of such treatment, a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: February 11, 2025
    Assignee: MacKay Memorial Hospital
    Inventors: Yeou-Ping Tsao, Tsung-Chuan Ho
  • Patent number: 12214010
    Abstract: Provided herein are desmopressin oral liquid formulations. Also provided herein are methods of making and using desmopressin oral liquid compositions for the treatment of certain diseases including diabetes insipidus, enuresis, hemophilia A, von willebrand disease, high blood urea levels and others.
    Type: Grant
    Filed: April 3, 2024
    Date of Patent: February 4, 2025
    Assignee: Tulex Pharmaceuticals Inc.
    Inventors: Yu-Hsing Tu, Kalyan Kathala, Romona Bhattacharya, Yingjun Fan, Ashok Perumal
  • Patent number: 12214059
    Abstract: The present application relates to a compound or a pharmaceutically acceptable salt and/or solvate thereof comprising one or more circulation enhancing groups, one or more target binding groups, one or more chelating groups, at one least cleavable linker and at least one branching group that is at least trivalent. The application further includes a radionuclide complex or a pharmaceutically acceptable salt and/or solvate thereof, comprising a compound of the application or a pharmaceutically acceptable salt and/or solvate thereof, and one or more radionuclides, and to compositions comprising the compound or the complexes. The present application also includes methods of using the compounds, complexes and compositions for targeting and/or killing target cells.
    Type: Grant
    Filed: March 13, 2024
    Date of Patent: February 4, 2025
    Assignee: FULL-LIFE TECHNOLOGIES HK LIMITED
    Inventors: Fa Liu, Alla Darwish
  • Patent number: 12214007
    Abstract: The present invention provides a fusion protein of BDNF and an anti-human transferrin receptor antibody, in which in a heavy chain variable region of the antibody, (a) CDR1 includes an amino acid sequence of SEQ ID NO: 66 or SEQ ID NO: 67, (b) CDR2 includes an amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 includes an amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 16.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: February 4, 2025
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hiroyuki Sonoda, Kenichi Takahashi
  • Patent number: 12195498
    Abstract: Provided is a separating agent that does not have a significantly reduced dynamic binding capacity (DBC) to a target substance even when the separating agent is continually CIP-treated under alkaline pH conditions. The separating agent includes a carrier and a protein, wherein the protein is a given protein, and a surface of the carrier and a lysine residue in the protein are bound by a chemical bond.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: January 14, 2025
    Assignees: NATIONAL UNIVERSITY CORPORATION KYOTO INSTITUTE OF TECHNOLOGY, DAICEL CORPORATION
    Inventors: Yoichi Kumada, Hiromichi Okura, Seiichi Uchimura
  • Patent number: 12195512
    Abstract: The present invention relates to ligand that may be a peptide compound as well as peptoid or retro-inverso analogues thereof with binding affinity for the Fc region of immunoglobulins. The invention further relates to the application of such peptides and variants thereof for purification of immunoglobulins on the basis of affinity chromatography, non-covalent antibody labelling, antibody detection or immobilization of antibodies to solid support.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: January 14, 2025
    Assignee: Univerza v Ljubljani
    Inventors: Nika Kruljec, Tomaž Bratkovič, Peter Molek, Mojca Lunder
  • Patent number: 12186361
    Abstract: This invention relates to drug delivery and in particular to the delivery of biologically active agents in the form of dry powders for inhalation. The invention also relates to methods for preparing such dry powder formulations and methods for their use.
    Type: Grant
    Filed: June 15, 2021
    Date of Patent: January 7, 2025
    Assignee: Monash University
    Inventors: Michelle McIntosh, David Morton, Tomas Sou, Livesey Olerile, Richard Prankerd
  • Patent number: 12173086
    Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.
    Type: Grant
    Filed: October 14, 2021
    Date of Patent: December 24, 2024
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
  • Patent number: 12146004
    Abstract: The present invention provides a compound of formula (I), and its use in methods of treatment, including the treatment of bacterial infections. Methods for the preparation of the compound of formula (I) are also provided.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: November 19, 2024
    Assignee: SPERO THERAPEUTICS, INC.
    Inventors: Pamela Brown, Michael Dawson, Mona Simonovic, Steven Boakes, Esther Duperchy, Steven James Stanway, Antoinette Wilson, Stephen Frederick Moss